Evidence map›Paper›PMID 39361721›Full record

ArticleInternational journal of STD & AIDS2025

Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States.

Sarah E Rutstein, Christopher Lopez, Thibaut Davy-Mendez, Harsh Agarwal, Hanna Huffstetler, Angela Perhac, Barbarajean Turner, Joseph J Eron, Vivian Go, Claire E Farel and 2 more

Abstract read
In one paragraph

Article in International journal of STD & AIDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sarah E RutsteinDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0002-1571-6576
Christopher LopezDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Thibaut Davy-MendezDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0002-8505-9268
Harsh AgarwalDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Hanna HuffstetlerDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Angela PerhacDepartment of Medicine, University of North Carolina Hospitals and Health Systems, Chapel Hill, NC, USA.
Barbarajean TurnerDepartment of Medicine, University of North Carolina Hospitals and Health Systems, Chapel Hill, NC, USA.
Joseph J EronDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Vivian GoDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Claire E FarelDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Kuo-Ping LiDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Sonia NapravnikDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
North Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5M
NCATS NIH HHS UM1 TR004406NIAID NIH HHS P30 AI050410
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Academic Medical CentersAnti-HIV AgentsHIV InfectionsPyridonesViral LoadAdultDelayed-Action PreparationsDiketopiperazinesEligibility DeterminationFemaleHIV-1HumansInjectionsMaleMiddle AgedRilpivirineAnti-HIV AgentscabotegravirDelayed-Action PreparationsDiketopiperazinesPyridonesRilpivirineHIVimplementationLong-acting injectablerurality

Identifiers

PMID39361721
PMCPMC11833706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.